Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

Shadi Chamseddine; Yehia I. Mohamed; Sunyoung S. Lee; James C. Yao; Zishuo Ian Hu; Hop S. Tran Cao; Lianchun Xiao; Ryan Sun; Jeffrey S. Morris; Rikita I. Hatia; Manal Hassan; Dan G. Duda; Maria Diab; Amr Mohamed; Ahmed Nassar; Saumil Datar; Hesham M. Amin; Ahmed Omar Kaseb

doi:10.1159/000531870

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

Shadi Chamseddine, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Zishuo Ian Hu, Hop S. Tran Cao, Lianchun Xiao, Ryan Sun, Jeffrey S. Morris, Rikita I. Hatia, Manal Hassan, Dan G. Duda, Maria Diab, Amr Mohamed, Ahmed Nassar, Saumil Datar, Hesham M. Amin, Ahmed Omar Kaseb

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients. Methods: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method. Results: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18. Conclusion: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC.

Original language	English (US)
Pages (from-to)	730-737
Number of pages	8
Journal	Oncology (Switzerland)
Volume	101
Issue number	11
DOIs	https://doi.org/10.1159/000531870
State	Published - Oct 1 2023

ASJC Scopus subject areas

Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1159/000531870

Cite this

Chamseddine, S., Mohamed, Y. I., Lee, S. S., Yao, J. C., Hu, Z. I., Tran Cao, H. S., Xiao, L., Sun, R., Morris, J. S., Hatia, R. I., Hassan, M., Duda, D. G., Diab, M., Mohamed, A., Nassar, A., Datar, S., Amin, H. M., & Kaseb, A. O. (2023). Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology (Switzerland), 101(11), 730-737. https://doi.org/10.1159/000531870

Chamseddine, S, Mohamed, YI , Lee, SS , Yao, JC , Hu, ZI , Tran Cao, HS , Xiao, L , Sun, R, Morris, JS, Hatia, RI, Hassan, M, Duda, DG, Diab, M, Mohamed, A, Nassar, A, Datar, S, Amin, HM & Kaseb, AO 2023, 'Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma', Oncology (Switzerland), vol. 101, no. 11, pp. 730-737. https://doi.org/10.1159/000531870

@article{817199e56b4b4807bbeffb5476d9c69c,

title = "Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma",

abstract = "Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients. Methods: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method. Results: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18. Conclusion: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC.",

author = "Shadi Chamseddine and Mohamed, {Yehia I.} and Lee, {Sunyoung S.} and Yao, {James C.} and Hu, {Zishuo Ian} and {Tran Cao}, {Hop S.} and Lianchun Xiao and Ryan Sun and Morris, {Jeffrey S.} and Hatia, {Rikita I.} and Manal Hassan and Duda, {Dan G.} and Maria Diab and Amr Mohamed and Ahmed Nassar and Saumil Datar and Amin, {Hesham M.} and Kaseb, {Ahmed Omar}",

year = "2023",

month = oct,

day = "1",

doi = "10.1159/000531870",

language = "English (US)",

volume = "101",

pages = "730--737",

journal = "Oncology (Switzerland)",

issn = "0030-2414",

publisher = "UBM Medica Healthcare Publications",

number = "11",

}

TY - JOUR

T1 - Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

AU - Chamseddine, Shadi

AU - Mohamed, Yehia I.

AU - Lee, Sunyoung S.

AU - Yao, James C.

AU - Hu, Zishuo Ian

AU - Tran Cao, Hop S.

AU - Xiao, Lianchun

AU - Sun, Ryan

AU - Morris, Jeffrey S.

AU - Hatia, Rikita I.

AU - Hassan, Manal

AU - Duda, Dan G.

AU - Diab, Maria

AU - Mohamed, Amr

AU - Nassar, Ahmed

AU - Datar, Saumil

AU - Amin, Hesham M.

AU - Kaseb, Ahmed Omar

PY - 2023/10/1

Y1 - 2023/10/1

N2 - Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients. Methods: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method. Results: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18. Conclusion: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC.

AB - Introduction: Circulating inflammatory cytokines play critical roles in tumor-associated inflammation and immune responses. Recent data have suggested that several interleukins (ILs) mediate carcinogenesis in hepatocellular carcinoma (HCC). However, the predictive and prognostic value of circulating ILs is yet to be validated. Our study aimed to evaluate the association of the serum ILs with overall survival (OS) and clinicopathologic features in a large cohort of HCC patients. Methods: We prospectively collected data and serum samples from 767 HCC patients treated at the University of Texas MD Anderson Cancer Center between 2001 and 2014, with a median follow-up of 67.4 months (95% confidence interval [CI]: 52.5, 83.3). Biomarker association with OS was evaluated by the log-rank method. Results: The median OS in this cohort was 14.2 months (95% CI: 12, 16.1 months). Clinicopathologic features were more advanced, and OS was significantly inferior in patients with high circulating levels of IL1-R1, IL-6, IL-8, IL-10, IL-15, IL-16, and IL-18. Conclusion: Our study shows that several serum IL levels are valid prognostic biomarker candidates and potential targets for therapy in HCC.

UR - http://www.scopus.com/inward/record.url?scp=85175741799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85175741799&partnerID=8YFLogxK

U2 - 10.1159/000531870

DO - 10.1159/000531870

M3 - Article

C2 - 37467732

AN - SCOPUS:85175741799

SN - 0030-2414

VL - 101

SP - 730

EP - 737

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

IS - 11

ER -

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this